A multimodal motor skill balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease
Objective: To study the effectiveness of Multimodal Motor Skill Balance Training (MBT) with rhythmical auditory cues to improve balance control and reduce falls in PD.…Classifying Parkinsonian Gait and Turning in Daily Life with Wearable Technology
Objective: We aim to determine the set of gait and turning measures from wearable technology that best separate mobility during daily life in people with…Is there a relationship between depression/anxiety and physical inactivity in Parkinson Disease?
Objective: To investigate the relationships between depression/anxiety and activity limitations in Parkinson disease (PD). Background: Depression, anxiety are common non-motor symptoms in PD. Depression which…Efficacy of prolonged release melatonin for REM sleep behaviour disorder in Parkinson’s disease: A double blind, randomised, placebo-controlled trial
Objective: Test the efficacy of prolonged-released melatonin for REM sleep behaviour disorder (RBD) in Parkinson’s disease (PD). Background: Half of all PD patients experience RBD…Long-term effect of subthalamic nucleus deep brain stimulation on freezing of gait in patients with advanced Parkinson’s disease
Objective: To investigate the long-term effect of subthalamic nucleus deep brain stimulation (STN-DBS) on freezing of gait (FOG) in patients with Parkinson's disease (PD) by…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily on Parkinson disease (PD) disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 177
- Next Page »